ClinicalTrials.gg
Active, not recruitingNCT06042478Updated Oct 14, 2026

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

A Phase 3 interventional study of Remibrutinib and Placebo to remibrutinib in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 110 sites in 23 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
2nd of 12
470 · median 347
Started
2023
with 2 others
Phase 3
9 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 9th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

The purpose of the core phase of the trial is to assess the efficacy, safety and tolerability of remibrutinib (LOU064) 25 milligrams (mg) twice a day (b.i.d.) over placebo for 24 weeks and in comparison to omalizumab 300 mg every 4 weeks (q4w) for 52 weeks in participants with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines (H1-AH).

The purpose of the open-label extension phase is to assess efficacy, safety and tolerability up to two years for patients treated with remibrutinib and patients transitioned from omalizumab to remibrutinib at Week 52. In the extension phase, treatment will be with remibrutinib only (i.e., no background therapy). The extension phase will also fulfill the Novartis commitment to provide post-trial access to participants of the previous core phase.

Read the detailed description

The study consists of 4 periods, and the total study duration is up to 112 weeks. Approximately 468 adult participants with CSU are expected to be randomized in the study.

Screening period: A screening period of up to 4 weeks will allow for the assessment of eligibility, determination of baseline disease activity and wash-out of prohibited medications.

Core Phase Treatment Period (52 weeks):

The treatment period will be double-dummy and double-blind, with placebo injections matching omalizumab 300 mg s.c. given to participants in the remibrutinib arm and placebo tablets matching remibrutinib 25 mg given to participants in the omalizumab arm (double-dummy). At the randomization visit, eligible participants will be randomized to one of four treatment arms.

Extension Phase Treatment Period (52 weeks): Optional open-label extension where patients receive treatment with open-label remibrutinib 25 mg, for 52 weeks.

Follow-up period:

For patients that do not enter the extension phase, there will be a 16-week, treatment-free, safety follow-up period.

Patients that enter extension phase will have a 4-week treatment-free safety follow-up period at the end of the extension phase.

All participants will be on a stable, local label-approved standard dose of a second-generation H1-AH ("background therapy") throughout the entire core phase (starting a minimum of 7 days prior to randomization until the end of the core phase).

In addition, to treat unbearable symptoms of CSU flare-ups, participants will be allowed to use a different second-generation H1-AH on an as-needed basis ("rescue therapy").

03

Conditions studied

  • Chronic Spontaneous Urticaria

Keywords

  • CSU
  • urticaria
  • LOU064
  • omalizumab
  • remibrutinib
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adult participants ≥18 years of age at the time of signing the .
  • CSU duration for ≥ 6 months prior to screening.
  • Diagnosis of CSU inadequately controlled by second generation H1-AH at the time of randomization, defined as:
  • The presence of itch and hives for ≥6 consecutive weeks prior to screening, despite the use of second-generation H1-AH during this time period.
  • UAS7 score (range 0-42) ≥16, ISS7 score (range 0-21) ≥ 6 and HSS7 score (range 0- 21) ≥ 6 during the 7 days prior to randomization (Day 1).
  • Documentation of hives within three months before randomization.
  • Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol.
  • Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1).

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to ligelizumab, omalizumab and other biologics with any effect in CSU, including anti-IgE therapies.
  • Significant bleeding risk or coagulation disorders.
  • History of gastrointestinal bleeding.
  • Requirement for anti- or anti-coagulant medication.
  • History or current hepatic disease.
  • Evidence of cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
  • Evidence of helminthic parasitic infection as evidenced by stools being positive for a pathogenic organism according to local guidelines.
  • Documented history of anaphylaxis.
  • Pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
470 participants (actual)

Study arms

  • Experimental
    Remibrutinib

    Participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 52 weeks.

    Drug: Remibrutinib

  • Placebo comparator
    Placebo to remibrutinib

    Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w.

    Drug: Placebo to remibrutinib

  • Placebo comparator
    Placebo to omalizumab

    Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d.

    Drug: Placebo to omalizumab

  • Active comparator
    Omalizumab

    participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d. for 52 weeks.

    Drug: Omalizumab

Interventions

  • Active treatment

  • DrugPlacebo to remibrutinib

    Placebo followed by active treatment

  • DrugPlacebo to omalizumab

    Placebo followed by active comparator

  • Active comparator

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in Weekly Urticaria Activity Score (UAS7)

    The UAS7 is the sum of the Weekly Hives Severity Score (HSS7 score) and the Weekly Itch Severity Score (ISS7 score). The possible range of the weekly UAS7 score is 0 - 42 (highest activity).

    Time frame: Week 12

Secondary outcomes

  1. Achievement of UAS7=0 (yes/no)

    Complete UAS7 response is UAS7 = 0

    Time frame: Week 12

  2. Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score

    The severity of the itch will be recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21.

    Time frame: Week 12

  3. Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score

    The hives (wheals) severity score, defined by number of hives, will be recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21.

    Time frame: Week 12

  4. Occurrence of treatment-emergent adverse events and serious adverse events (SAEs)

    To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)

    Time frame: up to 68 weeks

07

Study locations

110 sites
  • Novartis Investigative Site
    CABA, Buenos Aires C1414AIF, Argentina
  • Novartis Investigative Site
    Mendoza, Mendoza Province M5500AFD, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DBS, Argentina
  • Novartis Investigative Site
    Bahía Blanca, B8000JRB, Argentina
  • Novartis Investigative Site
    CABA, C1012AAY, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90560-032, Brazil
  • Novartis Investigative Site
    Alphaville Barueri, São Paulo 06454-010, Brazil
  • Novartis Investigative Site
    Santo André, São Paulo 09060-870, Brazil
  • Novartis Investigative Site
    Sorocaba, São Paulo 18040-425, Brazil
  • Novartis Investigative Site
    Sofia, 1421, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Varna, 9009, Bulgaria
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1C3, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8L 3C3, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8S 1G5, Canada
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
  • Novartis Investigative Site
    Niagara Falls, Ontario L2H 1H5, Canada
  • Novartis Investigative Site
    Québec, Quebec G1V 4W2, Canada
  • Novartis Investigative Site
    Verdun, Quebec H4G 3E7, Canada
  • Novartis Investigative Site
    Brno, 602 00, Czechia
  • Novartis Investigative Site
    Plzen Bolevec, 323 00, Czechia
  • Novartis Investigative Site
    Prague, 100 34, Czechia
  • Novartis Investigative Site
    Nice, France 06000, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    La Rochelle, 17019, France
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
  • Novartis Investigative Site
    Hamburg, Free and Hanseatic City of Hamburg 22391, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Stade, Lower Saxony 21682, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06120, Germany
  • Novartis Investigative Site
    Bad Bentheim, 48455, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bochum, 44793, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    München, 80377, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Osnabrück, 49074, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Kaposvár, 7400, Hungary
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380016, India
  • Novartis Investigative Site
    Bangalore, Karnataka 560004, India
  • Novartis Investigative Site
    Belagavi, Karnataka 590010, India
  • Novartis Investigative Site
    Mysore, Karnataka 570001, India
  • Novartis Investigative Site
    Nagpur, Maharashtra 440012, India
  • Novartis Investigative Site
    Nagpur, Maharashtra 440015, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422101, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
  • Novartis Investigative Site
    Bikaner, Rajasthan 334003, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500004, India
  • Novartis Investigative Site
    Dehradun, Uttarakhand 248001, India
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Roma, RM 00186, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Muar town, Johor 84000, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, Kuala Lumpur 50586, Malaysia
  • Novartis Investigative Site
    Ipoh, Perak 30450, Malaysia
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
  • Novartis Investigative Site
    Petaling Jaya, Selangor 46150, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Wilayah Persekutuan, 62502, Malaysia
  • Novartis Investigative Site
    Guadalajara, Jalisco 44638, Mexico
  • Novartis Investigative Site
    Cuauhtémoc, Mexico City 06100, Mexico
  • Novartis Investigative Site
    Villahermosa, Tabasco 86035, Mexico
  • Novartis Investigative Site
    Mérida, Yucatán 97070, Mexico
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Krosno, Krosno 38-400, Poland
  • Novartis Investigative Site
    Gdansk, 80-214, Poland
  • Novartis Investigative Site
    Gdansk, 80-546, Poland
  • Novartis Investigative Site
    Trnava, Slovakia 917 02, Slovakia
  • Novartis Investigative Site
    Bardejov, 085 01, Slovakia
  • Novartis Investigative Site
    Kežmarok, 060 01, Slovakia
  • Novartis Investigative Site
    Svidník, 089 01, Slovakia
  • Novartis Investigative Site
    Ansan, Gyeonggi-do 15355, South Korea
  • Novartis Investigative Site
    Busan, 49241, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Granada, Andalusia 18014, Spain
  • Novartis Investigative Site
    Barcelona, Catalonia 08003, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Las Palmas GC, 35010, Spain
  • Novartis Investigative Site
    Valencia, 46015, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Songkhla, Hat Yai 90110, Thailand
  • Novartis Investigative Site
    Khon Kaen, THA 40002, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand

Showing the first 100 of 110 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Sep 2025, 22 months.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 22 months is close to that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2023
First posted
Sep 18, 2023
StartActual
Nov 15, 2023
Primary completionActual
Sep 17, 2025
CompletionEst.
Jul 20, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06042478
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Nov 15, 2023
Primary completion
Sep 17, 2025
Completion
Jul 20, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion